Bli medlem
Bli medlem

Du är här

2015-03-27

Bionor Pharma ASA: Bionor announces additions to the executive management team and interim CFO

(Oslo, 27.03.2015) Bionor Pharma ASA (OSE:BIONOR) announces new members of the
executive management team joining CEO, Dr. David Horn Solomon. The new
members of the Company's executive management are all seasoned executives
with prior experience from listed healthcare companies. Joining the team are:

· Barbara A. Ruskin, Ph.D., J.D. - Senior Vice President, General Counsel and
Chief Patent Officer

Dr. Barbara Ruskin joins Bionor on April 1, 2015. Dr. Ruskin has acted for
over two decades advising diverse clients in the biotechnology and
pharmaceutical industries. She has broad expertise in worldwide patent
portfolio management, litigation strategies, corporate transactions and due
diligence on behalf of companies and investors. She holds a J.D. from Fordham
University School of Law (New York, NY), a Ph.D. in Biochemistry and
Molecular Biology from Harvard University (Cambridge, MA) and a B.A. in
Biochemistry from the University of California, Berkeley (Berkeley, CA). She
is admitted to practice law in New York State and is a registered U.S. patent
attorney. In addition to serving as Chief Patent Officer, Barbara will
oversee all legal affairs for Bionor.

· Kamilla Rolsted, Ph.D., MBA - Senior Vice President, Chief Strategy and
Business Officer

Dr. Kamilla Rolsted joins Bionor on April 1, 2015. Dr. Rolsted has more than
15 years of experience from academia and the pharmaceutical industry, and has
held various scientific and managerial positions. Most recently at Zealand
Pharma (Nasdaq CO: ZEAL), where Kamilla served as Director, heading Strategy
and Planning. Dr. Rolsted is a certified pharmacist, holds a Ph.D. in drug
metabolism from the University of Copenhagen and an executive MBA from
Copenhagen Business School. Kamilla will be responsible for strategy and
business development at Bionor.

· Søren Keller - Senior Vice President, Chief Operating Officer and Interim
Chief Financial Officer

Søren Keller has extensive experience as head of operations in both public and
private research intensive organizations. Prior to joining Bionor, Søren
served as director and general counsel to the management at Zealand Pharma
A/S (Nasdaq CO: ZEAL). Søren Keller received his master of Business
Administration and Commercial Law from Copenhagen Business School (CBS) and
continues to serve as a part-time lecturer at CBS. Søren will be responsible
for all operations at Bionor. Additionally, Søren will serve as Interim CFO
until the search for a permanent CFO is completed.

David Solomon, President and CEO commented "I am delighted that Barbara
Ruskin, Kamilla Rolsted and Søren Keller have joined Bionor. Together, they
bring a wealth of experience to advance therapeutic vaccines for Bionor, and
specifically will add operational strength to get our HIV functional cure
approach advanced to patients and the markets. "

Lars H. Høie, Chairman of the Board of Directors, says "With a new and proven
CEO in place in David Solomon, it is exciting to now have his experienced and
able management team also working to drive value for Bionor and bring
important solutions to HIV patients. Barbara, Kamilla and Søren are
significant additions to Bionor to advance the company's mission and on
behalf of the Board, I welcome them to the company."

Contact:
Cecilie Grue
Director of Legal Affairs
E-mail:cg@bionorpharma.com

Phone: +4799162486

David Horn Solomon
CEO
E-mail:dhs@bionorpharma.com

Phone: +45 22 20 63 00

About Bionor
Bionor Pharma ASA is a leading biotechnology company listed on the Oslo Stock
Exchange (OSE:BIONOR). The Company's focus is the research and development of
peptide based vaccines against viral diseases, primarily HIV. Bionor's
current clinical development pipeline comprises two vaccine candidates for
the treatment of HIV, Vacc-4x and Vacc-c5. Vacc-4x is one of the furthest
advanced therapeutic vaccines in the HIV space and has demonstrated a
reduction of viral load in a large randomized controlled phase II trial and
is currently being investigated in two phase II trials in collaboration with
Celgene Inc.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire

HUG#1906753

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.